Lexaria Bioscience Corp. has announced the final results from its Human Pilot Study #5 (GLP-1-H25-5), evaluating oral DehydraTECH-liraglutide ("DHT-LIR") capsules compared to injected Saxenda® branded liraglutide ("SAX-LIR"). The study demonstrated broadly similar temporal patterns between oral DHT-LIR and injected SAX-LIR, with the primary safety and tolerability endpoint achieved. Lexaria reported that the oral formulation functioned comparably to the injected version, despite using a conservatively low dose of DHT-LIR. The company is considering further development and potential commercialization of the oral product through the 505(b)(2) regulatory pathway and is in discussions with pharmaceutical partners. The results from this study have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1133839) on February 05, 2026, and is solely responsible for the information contained therein.